ライフサイエンスコーパス: target protein

1 g receptor and the extracellular domain of a target protein.

2 mall-molecule hotspots on the surface of the target protein.

3 examined are functional for binding to their target protein.

4 t epitopes covering the entire sequence of a target protein.

5 mational stability and interactions with the target protein.

6 ine/phosphothreonine at the C-termini of the target protein.

7 atically increase its binding affinity for a target protein.

8 es after the addition of known amount of the target protein.

9 PfGDH was used in the aptaFET to capture the target protein.

10 of reporter nanoparticles containing IL-6 as target protein.

11 ased in vivo DNA delivery, resulting in more target protein.

12 he soluble fraction amounts of the expressed target protein.

13 n, toxicity or insufficient stability of the target protein.

14 x, YBX1 was identified as the directly-bound target protein.

15 n and proteasomal-dependent degradation of a target protein.

16 3 central WW domains that bind PY motifs in target proteins.

17 ER that elongate and degrade PAR polymers on target proteins.

18 ing the interactions between viperin and its target proteins.

19 ave focussed on the effectors and their host target proteins.

20 mined by the native expression levels of the target proteins.

21 ch in turn will phosphorylate its downstream target proteins.

22 ical actions via cysteine S-sulfhydration of target proteins.

23 el, and enhanced the expression of HNF4alpha target proteins.

24 on the 2D map, may bind the same or similar target proteins.

25 Pro-x-Tyr (PPxY) motif contained in specific target proteins.

26 idal assemblies that nonspecifically inhibit target proteins.

27 tly relies on assays tailored for individual target proteins.

28 sites in conjunction with identification of target proteins.

29 ited a broad selectivity over a panel of off-target proteins.

30 lents might also be transferred from Prxs to target proteins.

31 leukocyte recruitment via cleavage of their target proteins.

32 sible for the addition of GlcNAc moieties to target proteins.

33 toswitchable regulation of a wide variety of target proteins.

34 ging, modulating and neutralizing endogenous target proteins.

35 with Prx can strongly impact the activity of target proteins.

36 fy molecules that bind with high affinity to target proteins.

37 l computational approach for predicting drug target proteins.

38 bution were then correlated to the amount of target proteins.

39 fying unknown interactions between drugs and target proteins.

40 bition including an effect on its downstream target proteins.

41 ium-dependent binding affinities to numerous target proteins.

42 and smaller noise propagation to downstream target proteins.

43 inked N-acetyl-d-glucosamine (O-GlcNAc) from target proteins.

44 SA), and bovine serum albumin (BSA) as model target proteins.

45 F-beta-activated kinase 1 (TAK1) as a DUSP11-targeted protein.

46 ase activity that induces the degradation of targeted proteins.

47 gradation, or signaling and localization, of targeted proteins.

48 ependent translocation to unfold and degrade targeted proteins.

49 diversity for multiple accessible pockets of targeted proteins.

50 rent presence of at least 3 mutations in the target proteins-2 in DNA gyrase (GyrA) and 1 in topoisom

51 However, targeted protein activation is chemically challenging, a

52 trometry-based screening approaches employ a target protein added to a pool of small-molecule compoun

53 D-L1 in over half the specimens and the drug target proteins all displayed different abundance patter

54 at the specificity of the nanobodies for the target protein allows the direct attainment of structura

55 nd structural properties of compounds and/or target proteins along with the experimentally verified b

56 scribe such an approach for the difficult-to-target protein alpha-synuclein encoded by the SNCA gene.

57 eased binding to the THOV nucleoprotein (NP) target protein and 10-fold higher anti-THOV restriction

58 s spectrometry (MS) involve the digestion of target protein and employ isotope-labeled peptide intern

59 ofluidic method for the rapid isolation of a target protein and its direct preparation for cryo-EM.

60 s exhibited K(d) <10 pM for their respective target protein and low cross-reactivity with five refere

61 xhibited a K(d) < 65 pM for their respective target protein and low cross-reactivity with four nonspe

62 improving the binding affinities towards the target protein and the E3 ligase, and optimizing the PRO

63 utlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53,

64 owing where an RNA molecule interacts with a target protein and/or engineering an RNA molecule to spe

65 ses deconjugate ubiquitin modifications from target proteins and are involved in many cellular proces

66 alyze posttranslational modification of many target proteins and have been suggested to play a role i

67 oncentrations was sufficient to saturate its target proteins and to block cellular FAO function.

68 ensure high-fidelity mapping of the antibody-targeted protein and improves the signal-to-noise ratio

69 tion, suggest a possible secondary mechanism targeting protein and DNA synthesis.

70 geneous biological network connecting drugs, targets (proteins) and diseases.

71 small-molecule binders of the kinase and the target protein, and exhibit several features of a bifunc

72 e systems, antibody probe hybridization to a target protein antigen depends on the interplay of dilut

73 lar, the association of an antibody with its target protein antigen is studied.

74 esponsible for the removal of ubiquitin from target proteins are poorly understood.

75 In conclusion, we found that Nrf2-targeted proteins are assigned to two groups: one mediat

76 It allows the user to specify the target protein as a PDB file and the ligand as a SMILES

77 ion of the linear molecule in complex with a target protein as the starting point, this approach iden

78 We have further identified the target protein as the tropomyosin alpha-4 chain (TPM4) b

79 hen used as a detection probe to capture the target protein at the biosensor surface allowing label-f

80 vice (RPD) for quantitative determination of targeted proteins at the fM concentration level.

81 ates formed in vitro selectively incorporate target proteins based on their surface charge, while cyt

82 Here we report a collagen type I targeting protein-based contrast agent (ProCA32.collagen

83 ulates in the light but does not destabilize target proteins before dusk.

84 2 complex is formed together with additional target proteins before ubiquitination and degradation th

85 wed in relation to the static structure of a target protein binding pocket.

86 a signaling-relevant phosphorylation of the target protein Bruton's tyrosine kinase in cells.

87 ading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency.

88 pLE) into inclusion bodies and releasing the target protein by cyanogen bromide (CNBr) cleavage; (ii)

89 reversible posttranslational modification of target proteins by covalent ligation of the small chaper

90 regulates the stability and functionality of target proteins by interacting in a noncovalent manner.

91 control functions and activities of specific target proteins by modulating the pool of ubiquitylated

92 [4Fe-4S] cluster assembly and insertion into target proteins by the mitochondrial iron-sulfur cluster

93 We demonstrated reductions in levels of the targeted proteins by Western blotting and used quantitat

94 Gid4 targets proteins by recognizing their N-terminal Pro res

95 es, but the structures of the complexes with target protein can only be determined for a small number

96 Reporter and targeting proteins can be modified and exposed on the su

97 weight that has been validated to bind to a target protein, can be an effective chemical starting po

98 in modification can alter the folding of the target protein; can affect binding interactions of the t

99 iptional factors (GATA3 and TBX21) and their target proteins (CCR4 and CXCR3).

100 have been achieved in live cell barcoding by targeting proteins (CD45, b2m, and CD298), by using smal

101 average of 45% overlap was found in plastid-targeted protein-coding gene families compared with Arab

102 with more effective and selective binding to target proteins compared to planar compounds with a high

103 projects requiring correlative microscopy to target protein complexes.

104 ant binding to other STATs or additional off-target proteins, confirming their exquisite specificity.

105 ystem for the sustained systemic delivery of targeted protein constructs with antifibrotic potential,

106 tein kinases catalyse the phosphorylation of target proteins, controlling most cellular processes.

107 roscopy (PDS), small-angle x-ray scattering, targeted protein cross-linking, and cryo-electron micros

108 al and experimental approaches, we show that target protein decay rates filter p53 pulses: Distinct t

109 ow that downstream pathways are sensitive to target protein decay rates.

110 Targeted protein degradation (TPD) has emerged as a powe

111 Targeted protein degradation (TPD) refers to the use of

112 (HyT) degrader by demonstrating the improved targeted protein degradation after pre-fusion the HyT de

113 Small molecule-induced targeted protein degradation by heterobifunctional ligan

114 (PROTACs) and related molecules that induce targeted protein degradation by the ubiquitin-proteasome

115 Viperin-targeted protein degradation contributes to the antivira

116 Targeted protein degradation has recently emerged as a n

117 re, we briefly discuss lessons learned about targeted protein degradation in chemical biology and dru

118 Our data suggests that targeted protein degradation is a promising drug develop

119 Targeted protein degradation is a promising drug develop

120 Targeted protein degradation is an important and pervasi

121 all, our work provides proof-of-concept that targeted protein degradation may provide a new paradigm

122 ases the challenges of developing drugs with targeted protein degradation mechanism.

123 mia, this Perspective highlights examples of targeted protein degradation observed for smaller, monom

124 We employed targeted protein degradation technology to convert a tau

125 Targeted protein degradation via cereblon (CRBN), a subs

126 Targeted protein degradation with bifunctional degraders

127 uitin ligases have so far been exploited for targeted protein degradation, and expansion of knowledge

128 Here we report an alternative mechanism of targeted protein degradation, in which a small molecule

129 ions related to fungal cell wall remodeling, targeted protein degradation, signal transduction, adhes

130 nmental cues pointing on manifold control of targeted protein degradation.

131 The discovery and development of targeted protein degraders have become important areas o

132 ggested that Cezanne recruitment to specific target proteins depends on UBA(Cez) Our results indicate

133 s highly specific because we observed no off-target protein destruction.

134 l by sortase, a cysteine transpeptidase that targets proteins displaying a cell wall sorting signal.

135 strates that in trans paired nicking retains target protein dosages in gene-edited cell populations a

136 h unbiased-omic approaches, we uncovered new target proteins, downstream pathways and molecular netwo

137 Traditional approaches would target proteins driving repeat mutations.

138 compound bioactivity space in the context of target proteins, drugs and drug candidate compounds.

139 n solutions through experimental screens and targeted protein engineering can be a difficult and time

140 Immobilization of a target protein enhances the cross-relaxation rates for t

141 (SUMO) proteins to a lysine (Lys) residue on target proteins, enhances EZH2 transcription.

142 Our tumor-targeting protein exhibits high avidity, minimal aggrega

143 nsmission cycle can be blocked by antibodies targeting proteins exposed on the parasite surface in th

144 tein decay rates filter p53 pulses: Distinct target protein expression dynamics are generated dependi

145 ation with proteomics data, we characterized target protein expression for pre-B leukemia immunothera

146 ng stress responses, how p53 pulsing affects target protein expression is not well understood.

147 Cell cycle tags allow to restrict target protein expression to specific cell cycle phases.

148 es by assessing microRNA (miRNA) expression, target protein expression, genetic loss, and silencing.

149 mains to be determined how p53 pulses impact target protein expression.

150 d resulted in a significant reduction of the targeted protein expression in corneal epithelium.

151 hly specific, reversible polymerization of a target protein, followed by its sequestration into cellu

152 rogel scaffolds have been used to immobilize target protein for immunoassay detection with fluorescen

153 at are dependent on nuclear-encoded, plastid-targeted proteins for all biochemical and regulatory fun

154 K1) on threonine 210, and phosphorylation of targeting protein for Xenopus Klp2 (TPX2) on serine 121.

155 Targeting protein for Xklp2 (TPX2) is an effector of bra

156 A kinase and its allosteric activator TPX2 (targeting protein for Xklp2), to experimentally characte

157 tinylation drives many cellular processes by targeting proteins for proteasomal degradation.

158 UBE3A is an E3 ubiquitin ligase that targets proteins for degradation and trafficking, so fin

159 The Arg/N-degron pathway targets proteins for degradation by recognizing their N-

160 The Arg/N-degron pathway targets proteins for degradation by recognizing their N-

161 Most commonly ubiquitination targets proteins for degradation/recycling by the 26S pr

162 f the complex contains an E3 RING domain and targets proteins for ubiquitin-dependent proteolysis.

163 ic activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand

164 ethod to exhaustively/quantitatively recover target proteins from tissues; and (iii) an appropriate s

165 Anaphase-promoting complex/cyclosome-CDH1 target proteins generally have D-Box or KEN-Box degron s

166 bacteria and bacteria-derived organelles by targeting proteins harboring leucine, phenylalanine, try

167 dates that form covalent linkages with their target proteins have been underexplored compared with th

168 molecules with a long residence time on the target protein, high permeability, and low efflux ratio

169 their high selectivity and specificity to a target protein, however, the understanding of SWNT hybri

170 the liver and the lack of specific membrane targeting proteins, HSC-targeted therapy remains a major

171 to select beads carrying peptides binding a target protein (human IgG).

172 ard a short peptide (i.e., the epitope) or a target protein (i.e., neuron specific enolase) in buffer

173 iBioProVis tool takes target protein identifiers and, optionally, compound SMI

174 on choosing an appropriate E3 ligase for the target protein, improving the binding affinities towards

175 , or identify sequence features found near a target protein in a ChIP-seq experiment.

176 nary complex (TC) when the ligand brings its target protein in contact with an E3 ubiquitin ligase.

177 r ultrasensitive, large-scale measurement of target protein in plasma and tissues.

178 -1)) allowed the direct determination of the target protein in raw plasma samples and in brain tissue

179 ression of HIF-1alpha and related downstream target proteins in adult rat brain.

180 any interactions of KimA and other potential target proteins in B. subtilis with c-di-AMP.

181 abling photoswitchable binding to endogenous target proteins in cells or light-based protein purifica

182 variety of highly active, unstable or stable target proteins in different living multicellular organi

183 therapeutic candidates to regulate specific target proteins in diverse diseases.

184 nd apply this probe to identify and quantify target proteins in intact human cells.

185 s often gain structure upon binding to their target proteins in multistep reactions involving the for

186 offset-triggered accurate quantification of target proteins in synchronous precursor selection (SPS)

187 and therefore directs the actual presence of target proteins in the cell.

188 ocesses, OTUB1 reduces the ubiquitylation of target proteins in two distinct ways, either by using it

189 ile, we further identified the possible MEHP-targeted proteins in living cells using the cellular the

190 tified Ces3 as a major lipid droplet surface-targeting protein in adipose tissue upon cold exposure b

191 nhibitors, as opposed to only binders to the target protein, in early steps of lead compound developm

192 re for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1,

193 lar processes in plants by rapidly degrading target proteins, including the repressors of hormone sig

194 pendent repression program, consisting of ER targeted proteins, including transmembrane proteins, gly

195 -Lindau (VHL) is an E3 ubiquitin ligase that targets proteins, including HIF-1alpha, for proteasomal

196 AIDA can be generally applicable for any target protein inside cells by involving appropriate pai

197 catalyzes an O-GlcNAc-modification onto key target proteins, integrates nutrient-signaling networks

198 osphatase 2A (PP2A) dephosphorylates several target proteins involved in cytoskeletal dynamics and ce

199 ges the phosphorylation status of known mTOR-target proteins involved in translational control, namel

200 e that the E. coli in-cell NMR spectrum of a target protein is a useful tool for monitoring the intra

201 ting a donor domain into every position of a target protein is not easily experimentally accessible.

202 Furthermore, a ZTL target protein is unable to accumulate to normal levels

203 The deubiquitylation of target proteins is mediated by deubiquitylating enzymes

204 a-N-acetylglucosamine to Ser/Thr residues on target proteins, is increasingly recognized as a critica

205 Analyzing hydrophobic motifs from similar LD-targeting proteins, it appears that the distribution of

206 signed to maintain affinity for bryostatin's target protein kinase C (PKC) while enabling exploration

207 AKAP1) is a multivalent binding protein that targets protein kinase A (PKA), RNAs, and other signalin

208 Targeting protein kinases is an important strategy for i

209 ve the structural distribution of one or two target proteins' known ligands on the 2D compound space,

210 moiety from NAD(+) to amino acid residues of target proteins, leading to mono- or poly-ADP-ribosylati

211 , however, processing optimization to elicit targeted protein modifications to balance quality and nu

212 interactions between the carrier and various target protein moieties a strategy of making permutated

213 choosing an optimal pair between particular target protein moiety and the best-suited original or sp

214 about minor groove width readout, we design targeted protein mutations that destabilize homeodomain

215 s associated with loss of myosin phosphatase-targeting protein MYPT1 and increase in the myosin phosp

216 are engineered to recognize and bind to the target protein of interest, DJ-1.

217 , which recruit E3 ligases to ubiquitinate a target protein of interest, have found wide application

218 confer light-switchable binding to a generic target protein of interest.

219 eNOS is a major target protein of the primary calcium-sensing protein ca

220 To identify target proteins of FBXW7 in CLL, we truncated the WD40 d

221 hosphoproteomics to decipher specific kinase target proteins of low abundance, of transient phosphory

222 Identifying the target proteins of small-molecule drug candidates is imp

223 xpression and purification using a set of 40 target proteins of various sizes, cellular localizations

224 s using probes specific for tumor-associated target proteins offers a powerful solution for providing

225 not depend on stereospecific engagement of a target protein or other chiral macromolecule, an observa

226 Whereas conventional antifungal strategies target proteins or cellular components essential for fun

227 rted PTM data, develop hypotheses related to target proteins or identify emergent patterns in PTM dat

228 initiation leading to N-terminally truncated target proteins or skipping of the edited exon leading t

229 In such screens, the target protein, or a synthetic epitope fragment of that

230 REGgamma mediated regulation of the REGgamma target protein p21 in vivo using p53-/- and p53/REGgamma

231 Therefore, targeting protein palmitoylation in AML blasts could blo

232 These findings indicate that targeting protein palmitoylation in AML could interfere

233 spectrometry (MS) to quantify immunotherapy target proteins PD-1, PD-L1, PD-L2, IDO1, LAG3, TIM3, IC

234 in small-molecule crystal structures and in target-protein pockets are utilized to identify potentia

235 Inducing degradation of a target protein presents several advantages relative to s

236 nd formation of the VS and that depletion of target proteins prevented virus trafficking to the plasm

237 firmation of entrenchment for all three drug-target proteins: protease, reverse transcriptase, and in

238 bioactive alpha-helical ligands developed to target protein-protein interactions.

239 eraction networks, including drug-drug, drug-target, protein-protein, and gene-disease interactions,

240 ore broadly, its discovery demonstrates that targeting protein-protein interactions found within the

241 lable for high-throughput screening of drugs targeting protein-protein interactions.

242 erived from brain tissue to evaluate whether targeted proteins putatively mediate the effects of gene

243 ssay that employed conjugated antibodies for target protein recognition, which when bound, altered th

244 Depletion of target proteins resulted in an accumulation of virus in

245 surface antigens show robust effects on the target proteins, resulting in hyperexcitability and impa

246 The specific binding of the target protein results in a change in the surface potent

247 alyses not only lead to novel insight into a target protein's function but can generate thought-provo

248 ucible degradation systems that preserve the target protein's native expression levels and patterns w

249 l molecule binding to endogenous, unmodified target protein(s) in cells.

250 generate the evolutionary information for a target protein, SeqVec created embeddings on average in

251 Following overexpression of the target protein, spin labeling is performed with E. coli

252 y bind to amino acids other than cysteine on target proteins such as glutathione S-transferase pi (GS

253 ere included in the epitope depending on the targeted protein supports the conclusion that 2C6 target

254 gainst a functionally relevant region of the target protein surface that varies in the different subt

255 le protein synthesis inhibition to show that targeted protein synthesis inhibition pan-neuronally and

256 By monitoring the abundance of target proteins that acquire their Fe-S clusters from NF

257 E3 ligase complex to degrade cellular/viral target proteins that are normally unaffected, A55 may al

258 xample kinases-AMPK and PKC-to phosphorylate target proteins that are not otherwise substrates for th

259 Here we analyze 37 target proteins that have bRo5 drugs or clinical candida

260 ferences in the effect of CDK5 on downstream target proteins that regulate memory.

261 mise for the development of new therapeutics targeting proteins that have evaded previous attempts at

262 an attractive alternative strategy involves targeting proteins that regulate fungal virulence or ant

263 However, the identities of Vpr target proteins through which these biological effects a

264 d NNTox, which uses predicted GO terms for a target protein to further predict the possibility of the

265 chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subseque

266 The assay was realized by capturing the target protein to the polymer microspheres.

267 he attachment of a variety of fusion tags to target proteins to meet the needs for different research

268 ransferase type I (GGTase-I), which normally target proteins to membranes for GTP-loading.

269 ules that preferentially bind phosphorylated target proteins to regulate a wide range of cellular fun

270 nable selective ubiquitin chain removal from target proteins to rescue the functional expression of d

271 O(2) oxidizes specific cysteine residues of target proteins to the sulfenic acid form and, similar t

272 finity ligands while reducing the demand for target-protein to less than a nanomole per selection.

273 k to correlate these predicted novel plastid-targeted proteins to transcript abundance and high-throu

274 ys key roles in many biological processes by targeting proteins to the cell wall; however, its roles

275 in reducing Lys-63 polyubiquitylation of its target protein TRAF3 (TNF receptor-associated factor 3).

276 ibited prostate cancer cell proliferation by targeting protein tyrosine kinase 6 (PTK6).

277 elies on successful proteolytic digestion of target proteins under acidic conditions to localize pert

278 ts accomplish the capture and detection of a target protein via two antibodies that tightly bind at l

279 These enzymes catalyze ubiquitination of target proteins via a mechanism different from that of c

280 the conjugation of Ub to a serine residue of target proteins via a phosphoribosyl linker (hence named

281 It has also obtained genes for kleptoplast-targeted proteins via horizontal gene transfer (HGT) tha

282 The covalent binding to the targeted proteins was confirmed by MS and time-dependent

283 With valosin-containing protein as a target protein, we show that the developed mLFS concept

284 ial inhibitory effects of these molecules on target proteins were investigated using docking and mole

285 a challenge to identify allosteric sites in target proteins where insertion of responsive domains pr

286 binding site for the CaM binding domain of a target protein, which also undergoes major conformationa

287 mitoyl-CoA, to specific cysteine residues on target proteins, which affects their stability, localiza

288 acted as a pre-concentration scheme for the target protein, while the natural antibody was responsib

289 ctors in altering the function of their host target proteins will reveal critical components of the p

290 in vivo affinity capture of a phosphorylated target protein with antibiotic resistance of Escherichia

291 tein; can affect binding interactions of the target protein with substrates, allosteric effectors, or

292 at posttranslationally modify themselves and target proteins with ADP-ribose (termed PARylation).

293 ough empirical ADC design, it is possible to target proteins with broad normal tissue expression.

294 a covalent posttranslational modification of target proteins with ubiquitin, has a profound effect on

295 These nAbs form part of a robust toolbox for targeting proteins with distinct and highly spatially-re

296 Type VI CRISPR enzymes are RNA-targeting proteins with nuclease activity that enable sp

297 ammaTurn, which performed well for both easy targets (proteins with weak sequence similarity in PDB)

298 ctivity of E3 ligases and potently degrade a target protein within cells can be a lengthy and unpredi

299 gron (AID) system enables rapid depletion of target proteins within the cell by applying the natural

300 th weak sequence similarity in PDB) and hard targets (proteins without detectable similarity in PDB)